Sohanya Roshan Cheng Karyopharm Therapeutics Inc. (KPTI) insider trading activity

Sohanya Roshan Cheng is EVP & Chief Commercial Officer of Karyopharm Therapeutics Inc.. Currently has a direct ownership of 34,314 shares of KPTI, which is worth approximately $220,295. The most recent transaction as insider was on Mar 04, 2025, when has been sold 3,445 shares (Common Stock) at a price of $6.29 per share, resulting in proceeds of $21,669. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 34.3K

91.51% 3M change

91.28% 12M change

Total Value Held $220,295

Sohanya Roshan Cheng Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 04 2025	SELL Open market or private sale	$21,669 $6.29 p/Share	3,445 Reduced 9.12%	34,314 Common Stock
Feb 28 2025	BUY Grant, award, or other acquisition	-	9,999 Added 20.94%	37,759 Common Stock
Sep 04 2024	SELL Open market or private sale	$3,856 $0.72 p/Share	5,356 Reduced 1.31%	404,051 Common Stock
Mar 01 2024	SELL Open market or private sale	$6,130 $1.2 p/Share	5,109 Reduced 1.28%	393,509 Common
Feb 29 2024	SELL Open market or private sale	$25,552 $1.17 p/Share	21,840 Reduced 5.19%	398,618 Common
Feb 28 2024	BUY Grant, award, or other acquisition	-	198,959 Added 32.12%	420,458 Common Stock
Jan 24 2024	BUY Grant, award, or other acquisition	-	14,167 Added 6.01%	221,499 Common Stock
Sep 01 2023	SELL Open market or private sale	$9,861 $1.33 p/Share	7,415 Reduced 3.51%	204,086 Common Stock
Jun 08 2023	SELL Open market or private sale	$4,321 $2.35 p/Share	1,839 Reduced 0.86%	211,501 Common Stock
Mar 01 2023	SELL Open market or private sale	$34,054 $3.03 p/Share	11,239 Reduced 5.06%	210,687 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	-	100,000 Added 31.06%	221,926 Common Stock
Aug 31 2022	BUY Grant, award, or other acquisition	-	30,000 Added 20.01%	119,949 Common Stock
Jun 13 2022	SELL Open market or private sale	$8,174 $5.27 p/Share	1,551 Reduced 1.7%	89,949 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	84,000 Added 47.86%	91,500 Common Stock
Jun 30 2021	BUY Grant, award, or other acquisition	-	7,500 Added 50.0%	7,500 Common Stock

Also insider at

SESN

Sesen Bio, Inc. Healthcare

Director

SRC